Genentech, a member of the Roche Group (RHHBY.OB), has decided to discontinue its phase III clinical studies of Crenezumab in early Alzheimer's disease, dubbed CREAD 1 and CREAD 2, as the compound was unlikely to meet the primary endpoint.
from RTT - Biotech http://bit.ly/2WpmP2F
via IFTTT
No comments:
Post a Comment